Скачать с ютуб Secondary HRQoL domains in the KarMMa study of ide-cel in myeloma в хорошем качестве

Secondary HRQoL domains in the KarMMa study of ide-cel in myeloma

Nina Shah, MD, University of California-San Francisco, San Francisco, CA, shares the details of an analysis of secondary health-related quality of life domains (HRQoL) in the KarMMa study (NCT03361748): A Phase II trial of idecabtagene vicleucel (ide-cel) in relapsed/refractory multiple myeloma patients. Ide-cel is a BCMA-targeted CAR T-cell therapy, shown to elicit deep responses in myeloma. Questionnaires were used at baseline, the day of treatment, and throughout follow up to assess the impact of ide-cel on secondary HRQoL domains. Overall, patients showed a clinically meaningful improvement in most functioning and symptom subscale scores with ide-cel treatment, as well as in future perspectives and body image. Symptoms such as nausea/vomiting, insomnia and diarrhea frequently remained stable. The results show that ide-cel can bring about clinical improvements without negatively impacting HRQoL domains. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.